A novel liver-specific fluorescent anti-cancer drug delivery system using indocyanine green
A novel liver-specific fluorescent anti-cancer drug delivery system using indocyanine green
复制标题
DOI：
10.1038/s41598-019-39269-0
复制
发表时间：
2019-02-28
影响因子：
4.6
通讯作者：
Hasegawa, Kiyoshi
中科院分区：
文献类型：
--
作者：
Inagaki, Yoshinori;Kokudo, Takashi;Hasegawa, Kiyoshi
吲哚菁绿色（ICG）仅在肝细胞及其恶性对应物肝细胞癌（HCC）中积累。我们已经开发了ICG结合的抗癌药物，并注意到它们在体外和体内的HCC细胞中的显著积累。ICG偶联的吉西他滨对正常细胞的毒性较低，并且在皮下肿瘤异种移植物中与单独的吉西他滨相比具有上级抗肿瘤作用。ICG偶联可以为肝癌的治疗提供一种新的荧光药物递送系统，该系统可用于诊断和治疗HCC。
Indocyanine green (ICG) accumulates only in hepatocytes and their malignant counterpart, hepatocellular carcinoma (HCC). We have developed ICG-conjugated anti-cancer drugs and noted their significant accumulation in HCC cells both in vitro and in vivo. ICG-conjugated gemcitabine was less toxic to normal cells and it had superior anti-tumor action compared to gemcitabine alone in a subcutaneous tumor xenograft. ICG conjugation can provide a novel fluorescent drug delivery system for treatment of liver cancer and this system can be used to both diagnose and treat HCC.